CABA vs. ALEC, ALLO, VALN, TSHA, FATE, ADPT, EDIT, VYGR, ITOS, and EXAI
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Alector (ALEC), Allogene Therapeutics (ALLO), Valneva (VALN), Taysha Gene Therapies (TSHA), Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), and Exscientia (EXAI). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.
Cabaletta Bio has lower revenue, but higher earnings than Alector. Cabaletta Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cabaletta Bio had 18 more articles in the media than Alector. MarketBeat recorded 20 mentions for Cabaletta Bio and 2 mentions for Alector. Cabaletta Bio's average media sentiment score of 0.44 beat Alector's score of 0.37 indicating that Alector is being referred to more favorably in the media.
Alector received 70 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 69.72% of users gave Cabaletta Bio an outperform vote while only 60.58% of users gave Alector an outperform vote.
Alector has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.
Alector currently has a consensus price target of $14.00, indicating a potential upside of 157.35%. Cabaletta Bio has a consensus price target of $34.33, indicating a potential upside of 178.00%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Alector.
85.8% of Alector shares are held by institutional investors. 14.0% of Alector shares are held by insiders. Comparatively, 9.9% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cabaletta Bio has a net margin of 0.00% compared to Cabaletta Bio's net margin of -125.11%. Alector's return on equity of -38.77% beat Cabaletta Bio's return on equity.
Summary
Cabaletta Bio beats Alector on 9 of the 17 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
